Search Videos and More
Triplet Therapy Shows Promise in Phase 2 Study in Chronic Lymphocytic Leukemia
Dana-Farber researchers find that combining a BCL-2 inhibitor with two other targeted agents is active in previously untreated CLL patients.Dana-Farber Research Publication, 9.1.2021
Mantle Cell Lymphoma Clinical Trials
Targeted combination therapy for mantle cell lymphoma with minimal residual disease assessment.Personalized Cancer Vaccine Helps Patient
Richard Boylan speaks out about his experience with a personalized kidney cancer vaccine, saying he's 'extraordinarily lucky.' He's part of a clinical trial at Dana-Farber Cancer Institute. His doctor, David Braun, MD, PhD, is one of the scientists leading the research.Study Sounds Note of Caution on Effectiveness of COVID-19 Vaccines for Patients with Lymphoid Malignancies
Patients with lymphoma or other lymphoid cancers should continue to take steps to protect themselves from COVID-19 even if they have been vaccinated against the disease, a new study led by investigators at Dana-Farber Cancer Institute reports.COVID-19 and Cancer: Screenings Rebound but Study Finds Disparities
Cancer screenings rebounded after a dramatic decline in the first months of the COVID-19 pandemic, but a new study found an increase in disparities among some screening tests during the pandemic.Vitamin D May Protect Against Young-Onset Colorectal Cancer
Consuming higher amounts of Vitamin D – mainly from dietary sources – may help protect against developing young-onset colorectal cancer or precancerous colon polyps, according to the first study to show such an association.Season 1, Episode 2: Behind the Science of the 2019 Nobel Prize
It’s hard to overstate just how important oxygen is to life on earth. Almost every living thing on the planet needs it to convert fuel into energy.Season 1, Episode 1: The Wolf in Sheep's Clothing
The parable of the wolf in sheep’s clothing tale reminds us that things aren’t always as they seem, that bad guys can dress up as good guys to do their bad guy things.Phenotype, Specificity and Avidity of Antitumour CD8+ T Cells in Melanoma
Dana-Farber's Giacomo Oliveira, PhD describes a study he led with Cathy Wu, MD, that appeared in Nature.Updated Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Clinical Trials
Sara Tolaney, MD, MPH discusses updated standardized definitions for efficacy endpoints in adjuvant breast cancer clinical trials: STEEP Version 2.0.Study Pairs Two Forms of Immunotherapy in Patients with Advanced Kidney Cancer
T cells revved up to attack tumors are turned into an army of loiterers. Cells keenly attuned to signals of infection or disease fail to pick up the faint notes of cancer. A clinical trial led by Dana-Farber researchers is addressing both of these issues in patients who have undergone surgery for kidney cancer but have a high risk of recurrence.